Updates on Clinical Trials in Oncology and Radiation-Clinical Trials in Oncology and Radiation

Video Transcription

Video Summary

In this webinar, Dr. Flores and Dr. Remner discuss updates in lung cancer management, specifically focusing on neoadjuvant and adjuvant therapy, as well as the use of immunotherapy in combination with radiation therapy. They explain that lung cancer treatment has significantly changed in recent years, with the introduction of targeted therapies and immunotherapy. They discuss the results of the ADORA trial, which showed that adjuvant therapy with osmirnib in patients with EGFR mutations significantly improved disease-free survival. They also discuss the use of neoadjuvant chemotherapy and immunotherapy in patients with non-small cell lung cancer, and explain that this combination has shown promising results in terms of pathologic complete response rates. They also highlight the importance of genomic testing in the management of lung cancer, as the treatment options are becoming more personalized. They discuss ongoing clinical trials that are examining the use of immunotherapy in combination with radiation therapy, and the potential for proton therapy and other novel radiation technologies to improve outcomes. They also mention the importance of monitoring for and managing immunotherapy-related toxicities, such as pneumonitis, and the need for multidisciplinary collaboration in the management of these patients. Overall, they emphasize that lung cancer treatment is rapidly evolving, and that the use of targeted therapies and immunotherapy has the potential to significantly improve outcomes for patients.

Keywords

lung cancer management

neoadjuvant therapy

adjuvant therapy

immunotherapy

radiation therapy

targeted therapies

ADORA trial

genomic testing

clinical trials

multidisciplinary collaboration